Can your genes predict breast cancer treatment success?

NCT ID NCT04638725

Recruiting now Knowledge-focused Sponsor: Centre Paul Strauss Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find genetic markers that may explain why some HER2-positive breast cancer patients respond well to treatment while others do not, or experience side effects. Researchers will collect blood samples from 9,000 participants and follow them for five years. The goal is to better understand treatment resistance and sensitivity, not to test a new therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institut de cancérologie Strasbourg Europe
RECRUITING

Strasbourg, 67033, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••